PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS?

National Health Technology Assessment (HTA) processes represent the most significant hurdle for new pharmaceuticals aiming to achieve market access, often requiring a substantially higher evidence base than that which is needed for regulatory approval. With the exception of the NICE FTA pathway, abbreviated pathways are restricted to new preparations of previously subsidized drugs, generics or biosimilars, with limited applicability in bringing innovative therapies to market. [Extracted from the article]